Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?

Eur Heart J. 2021 May 7;42(18):1808. doi: 10.1093/eurheartj/ehaa948.

Author

Kwang Kon Koh^{1

2}

Affiliations

¹ Department of Cardiovascular Medicine, Heart Center, Gachon University, Gil Medical Center, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, Korea.
² Gachon Cardiovascular Research Institute, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, Korea.

PMID: 33351895
DOI: 10.1093/eurheartj/ehaa948

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Atherosclerosis* / prevention & control
Biomarkers
Cardiovascular Diseases* / prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Primary Prevention

Substances

Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors